Pelago Bioscience AB, is the exclusive licensee for the patented Cellular Thermal Shift Assay (CETSA®), and was founded to develop and provide services based on CETSA®. This assay is uniquely able to measure drug-target interactions in-situ within the cellular environment and can be applied against a specified protein target or in a non-targeted proteomics study. Critically CETSA assays require no modification to the ligand or target as they utilize the natural thermodynamic properties of the protein itself and can be applied to any cell or sample type. Pelago works exclusively on CETSA, and is able to offer full assay development and screening services to its customers using its own dedicated laboratories in Sweden.
Solna, 171 48 Sweden